Clinical

Dataset Information

0

The optimal cut off value of KRAS testing for the selection of unresectable colorectal cancer patients more likely to benefit from treatment with anti-EGFR in the first line setting.

ABSTRACT: Primary outcome(s): Progression-free survival (PFS)

DISEASE(S): Colorectal Cancer

PROVIDER: 2642323 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Selection on Optimal Haploid Value Increases Genetic Gain and Preserves More Genetic Diversity Relative to Genomic Selection.
| S-EPMC4574260 | biostudies-literature
Unknown Does more testing in routine preoperative evaluation benefit the orthopedic patient? Case control study from a resource-constrained setting.
| S-EPMC8181773 | biostudies-literature
Unknown Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.
| S-EPMC3139487 | biostudies-literature
Unknown Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.
| S-EPMC6145687 | biostudies-literature
Unknown Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation.
| S-EPMC7504481 | biostudies-literature
Unknown AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
| S-EPMC7376720 | biostudies-literature
Unknown KRAS Testing: Optimizing Cancer Therapy.
| S-EPMC2816163 | biostudies-literature
Unknown Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis.
| S-EPMC5557867 | biostudies-literature
Unknown Quantitative proteomics of small numbers of closely-related cells: Selection of the optimal method for a clinical setting.
| S-EPMC9553008 | biostudies-literature
Unknown <i>KRAS</i> mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting.
| S-EPMC7399406 | biostudies-literature